Cizzle Bio Expands Lung Cancer Test Licensing to the Caribbean
At Cizzle Bio, Inc., we’re excited to announce a major milestone: the extension of our exclusive licensing agreement for the CIZ1B Biomarker Test to include the 14 Sovereign States of the Caribbean and the Cayman Islands. This partnership marks a significant step forward in our mission to detect cancer early and save lives.
Key Highlights
Broader Reach: The CIZ1B lung cancer blood test will now be available to over 45 million people in the Caribbean, expanding access to early lung cancer detection.
Early Royalty Payments: The agreement accelerates advanced royalty payments, with $500,000 payable in 2025, supporting cash flow for growth initiatives.
CAP Accreditation Progress: Cizzle Bio has signed its first agreement with a CAP-approved clinical laboratory, with plans to achieve CLIA accreditation in January 2025 and launch commercially in April 2025.
Strategic Partnerships: This expansion was driven by BIO investor interest and healthcare connections in the Caribbean, demonstrating the increasing demand for early cancer detection solutions.
The Caribbean Opportunity
The Caribbean region presents a unique opportunity to increase ethnic representation in lung cancer diagnostic data and expand commercial reach. This collaboration aligns with our mission to bring innovative, non-invasive, and cost-effective diagnostic solutions to diverse populations.
Looking Ahead
We are committed to building strong partnerships with clinicians, hospitals, and laboratories, furthering our goal to save lives through early cancer detection. With the addition of the Caribbean region, we are advancing our efforts to make the CIZ1B Biomarker Test a global standard in lung cancer diagnostics.
